酪氨酸酶抑制剂治疗儿童费城染色体阳性的 急性淋巴细胞白血病的研究进展
Research Progress in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Children with Tyrosine Kinase Inhibitors
摘要: 费城染色体阳性的急性淋巴细胞白血病(Philadelphia chromosome-positive acute lymphoblastic leukemia, Ph+ ALL)在儿童白血病中的发病率虽不高，但因其治疗效果差，一直以来都是难以攻克的难题。直到酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)的出现扭转了这种局面，让此类型的白血病患者的预后明显改善，结合其他前沿治疗，极大地推动了治疗方案的优化、促进低强度化疗甚至去化疗方案成为可能。本文将重点介绍TKI治疗儿童Ph+ ALL的最新进展，旨在为临床治疗提供更多选择和方向。
Abstract: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) accounts for a low incidence among pediatric acute lymphoblastic leukemia cases, and its historically poor treatment outcomes have made it a persistent therapeutic challenge. The advent of tyrosine kinase inhibitors (TKIs) has dramatically transformed this landscape, significantly improving prognosis for these patients. When combined with other cutting-edge therapies, TKIs have greatly optimized treatment strategies, even making low-intensity chemotherapy or chemotherapy-free regimens a viable possibility. The review focuses on recent advances in TKI-based therapies for pediatric Ph+ ALL, aiming to provide clinicians with more options and future directions.
文章引用：陈玉莹, 于洁. 酪氨酸酶抑制剂治疗儿童费城染色体阳性的 急性淋巴细胞白血病的研究进展[J]. 临床医学进展, 2026, 16(4): 3137-3143. https://doi.org/10.12677/acm.2026.1641572

参考文献

[1] Malard, F. and Mohty, M. (2020) Acute Lymphoblastic Leukaemia. The Lancet, 395, 1146-1162. [Google Scholar] [CrossRef] [PubMed]
[2] Aricò, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., et al. (2000) Outcome of Treatment in Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 342, 998-1006. [Google Scholar] [CrossRef] [PubMed]
[3] Aricò, M., Schrappe, M., Hunger, S.P., Carroll, W.L., Conter, V., Galimberti, S., et al. (2010) Clinical Outcome of Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated between 1995 and 2005. Journal of Clinical Oncology, 28, 4755-4761. [Google Scholar] [CrossRef] [PubMed]
[4] Foà, R. and Chiaretti, S. (2022) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 386, 2399-2411. [Google Scholar] [CrossRef] [PubMed]
[5] Schultz, K.R., Bowman, W.P., Aledo, A., Slayton, W.B., Sather, H., Devidas, M., et al. (2009) Improved Early Event-Free Survival with Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Journal of Clinical Oncology, 27, 5175-5181. [Google Scholar] [CrossRef] [PubMed]
[6] Slayton, W.B., Schultz, K.R., Kairalla, J.A., Devidas, M., Mi, X., Pulsipher, M.A., et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial Aall0622. Journal of Clinical Oncology, 36, 2306-2314. [Google Scholar] [CrossRef] [PubMed]
[7] Schultz, K.R., Carroll, A., Heerema, N.A., Bowman, W.P., Aledo, A., Slayton, W.B., et al. (2014) Long-Term Follow-Up of Imatinib in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Children’s Oncology Group Study Aall0031. Leukemia, 28, 1467-1471. [Google Scholar] [CrossRef] [PubMed]
[8] Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., et al. (2012) Imatinib after Induction for Treatment of Children and Adolescents with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukaemia (Esphall): A Randomised, Open-Label, Intergroup Study. The Lancet Oncology, 13, 936-945. [Google Scholar] [CrossRef] [PubMed]
[9] O’Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., et al. (2005) In Vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research, 65, 4500-4505. [Google Scholar] [CrossRef] [PubMed]
[10] Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barrish, J.C., Behnia, K., et al. (2004) Discovery of n-(2-Chloro-6-Methyl-Phenyl)-2-(6-(4-(2-Hydroxyethyl)-Piperazin-1-Yl)-2-Methylpyrimidin-4-Ylamino)Thiazole-5-Carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays. Journal of Medicinal Chemistry, 47, 6658-6661. [Google Scholar] [CrossRef] [PubMed]
[11] Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., et al. (2020) Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncology, 6, 358-366. [Google Scholar] [CrossRef] [PubMed]
[12] Hunger, S.P., Tran, T.H., Saha, V., Devidas, M., Valsecchi, M.G., Gastier-Foster, J.M., et al. (2023) Dasatinib with Intensive Chemotherapy in de Novo Paediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (CA180-372/COG AALL1122): A Single-Arm, Multicentre, Phase 2 Trial. The Lancet Haematology, 10, e510-e520. [Google Scholar] [CrossRef] [PubMed]
[13] Stirrups, R. (2020) Dasatinib versus Imatinib for Childhood Acute Lymphocytic Leukaemia. The Lancet Oncology, 21, e73. [Google Scholar] [CrossRef] [PubMed]
[14] Jabbour, E., Kantarjian, H.M., Aldoss, I., Montesinos, P., Leonard, J.T., Gómez-Almaguer, D., et al. (2024) Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA, 331, 1814-1423. [Google Scholar] [CrossRef] [PubMed]
[15] O’Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A., Rivera, V.M., Wang, F., et al. (2009) AP24534, a Pan-Bcr-Abl Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer Cell, 16, 401-412. [Google Scholar] [CrossRef] [PubMed]
[16] Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., et al. (2010) Structural Mechanism of the Pan‐Bcr‐Abl Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance. Chemical Biology & Drug Design, 77, 1-11. [Google Scholar] [CrossRef] [PubMed]
[17] Li, X., Zhang, J., Liu, F., Liu, T., Zhang, R., Chen, Y., et al. (2023) Olverembatinib Treatment in Pediatric Patients with Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia, 23, 660-666. [Google Scholar] [CrossRef] [PubMed]
[18] Pui, C., Campana, D., Pei, D., Bowman, W.P., Sandlund, J.T., Kaste, S.C., et al. (2009) Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 360, 2730-2741. [Google Scholar] [CrossRef] [PubMed]
[19] Brown, P.A., Ji, L., Xu, X., Devidas, M., Hogan, L.E., Borowitz, M.J., et al. (2021) Effect of Postreinduction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults with First Relapse of B-Cell Acute Lymphoblastic Leukemia. JAMA, 325, 833-842. [Google Scholar] [CrossRef] [PubMed]
[20] Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M.S., et al. (2017) Complete Hematologic and Molecular Response in Adult Patients with Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment with Blinatumomab: Results from a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35, 1795-1802. [Google Scholar] [CrossRef] [PubMed]
[21] Pennesi, E., Michels, N., Brivio, E., van der Velden, V.H.J., Jiang, Y., Thano, A., et al. (2022) Inotuzumab Ozogamicin as Single Agent in Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia: Results from a Phase II Trial. Leukemia, 36, 1516-1524. [Google Scholar] [CrossRef] [PubMed]
[22] O’Brien, M.M., Ji, L., Shah, N.N., Rheingold, S.R., Bhojwani, D., Yuan, C.M., et al. (2022) Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children’s Oncology Group Protocol Aall1621. Journal of Clinical Oncology, 40, 956-967. [Google Scholar] [CrossRef] [PubMed]
[23] Zhai, Y., Hong, J., Wang, J., Jiang, Y., Wu, W., Lv, Y., et al. (2024) Comparison of Blinatumomab and CAR T-Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Expert Review of Hematology, 17, 67-76. [Google Scholar] [CrossRef] [PubMed]
[24] Leonard, J.T., Rowley, J.S.J., Eide, C.A., Traer, E., Hayes-Lattin, B., Loriaux, M., et al. (2016) Targeting BCL-2 and ABL/LYN in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Science Translational Medicine, 8, 354ra114. [Google Scholar] [CrossRef] [PubMed]
[25] Xiao, X., Liu, P., Li, D., Xia, Z., Wang, P., Zhang, X., et al. (2020) Combination Therapy of Bcr-Abl-Positive B Cell Acute Lymphoblastic Leukemia by Tyrosine Kinase Inhibitor Dasatinib and C-Jun N-Terminal Kinase Inhibition. Journal of Hematology & Oncology, 13, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[26] Pfeifer, H., Wassmann, B., Hofmann, W.K., Komor, M., Scheuring, U., Brück, P., Binckebanck, A., Schleyer, E., Gökbuget, N., Wolff, T., Lübbert, M., Leimer, L., Gschaidmeier, H., Hoelzer, D. and Ottmann, O.G. (2003) Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate. Clinical Cancer Research, 9, 4674-4681.
[27] Jabbour, E., Haddad, F.G., Short, N.J. and Kantarjian, H. (2022) Treatment of Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. JAMA Oncology, 8, 1340-1348. [Google Scholar] [CrossRef] [PubMed]
[28] Soverini, S., Bassan, R. and Lion, T. (2019) Treatment and Monitoring of Philadelphia Chromosome-Positive Leukemia Patients: Recent Advances and Remaining Challenges. Journal of Hematology & Oncology, 12, Article No. 39. [Google Scholar] [CrossRef] [PubMed]

为你推荐